BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, is investigating whether Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its executives may be liable for securities fraud. If you purchased or acquired shares of Applied Therapeutics and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at [email protected], or at https://www.blockleviton.com/cases/aplt.

On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration had placed a partial clinical hold on the Company’s ACTION-Kids study, evaluating the Company’s AT-007 product for the treatment of galactosemia. The FDA cited the need for additional technical information relating to ensuring that each study participant has access to the drug’s benefits. On this news, shares of Applied Therapeutics’ stock fell $3.53 per share, or 12.07%, to close at $25.71.

If you purchased or acquired shares of Applied Therapeutics and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at [email protected], or at https://www.blockleviton.com/cases/aplt.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com